Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00656474 · ClinicalTrials.gov registry record · Phase 1
Efficacy Study of GLYC-101 to Evaluate Outcomes After Post-laser Ablation
A Phase 1 study, sponsored by TR Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT00656474: Completed Phase 1 study, sponsored by TR Therapeutics.
NCT00656474 is a Phase 1 study that has completed, run by TR Therapeutics. The registered enrollment target is 12 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (80% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00656474, a Phase 1 study, has completed, sponsored by TR Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
Study is intended to evaluate safety and efficacy parameters in patients treated with GLYC-101 gel or placebo after laser ablation.
Primary Outcome
Subjects were evaluated every 2 days from the time of the laser procedures for the first 10 days and then seen every 2 weeks for 4 weeks. Efficacy was assessed based on the time to complete epithelialization in terms of the number of days from Day 1 (day of laser ablation) to the day on which complete epithelialization was observed.
Interventions
- DRUG Placebo gel
- DRUG GLYC-101 gel (1.0 %)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2008-03 |
| Est. Completion | 2008-08 |
| Phase | Phase 1 |
What the finished NCT00656474 record still lists
NCT00656474 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (80% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo gel is the first listed.
NCT00656474 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00656474 about?
NCT00656474 is a clinical study titled "Efficacy Study of GLYC-101 to Evaluate Outcomes After Post-laser Ablation". Study is intended to evaluate safety and efficacy parameters in patients treated with GLYC-101 gel or placebo after laser ablation.
What is the current status of trial NCT00656474?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2008-03. Estimated completion is 2008-08.
What interventions are being tested in trial NCT00656474?
The interventions under investigation include: Placebo gel (DRUG), GLYC-101 gel (1.0 %) (DRUG).
Who is sponsoring clinical trial NCT00656474?
This trial is sponsored by TR Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00656474's enrollment target sits among peer trials
12 1852nd of 2000 higher than 90 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02602769 · 12 participants
Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome
- NCT02605421 · 12 participants · Phase 2
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
- NCT02619448 · 12 participants · Early Phase 1
Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC
- NCT03311503 · 12 participants · Phase 1
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia